Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Titan Pharmaceuticals Inc (NASDAQ:TTNP)

1.95
Delayed Data
As of 3:59pm ET
 0.00 / 0.00%
Today’s Change
1.75
Today|||52-Week Range
6.40
-51.25%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$41.3M

Company Description

Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Contact Information

Titan Pharmaceuticals, Inc.
400 Oyster Point Boulevard
South San Francisco California 94080-1921
P:(650) 244-4990
Investor Relations:
(650) 989-2215

Employees

Shareholders

Mutual fund holders5.54%
Individual stakeholders2.56%
Other institutional10.20%

Top Executives

Sunil BhonslePresident, Chief Executive Officer & Director
Brian CrowleyPrincipal Accounting Officer & VP-Finance
Katherine L. Glassman-BeebeChief Development Officer & Executive VP
Stephen KilmerInvestor Relations Contact